News for PAVmed Inc. (PAVM)

PR NewswireNEW YORK, April 11, 2025 NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial

Lucid Diagnostics (LUCD) successfully raised $16.1 million in net proceeds from a public offering. The offering included 14,375,000 shares at $1.20 per

PR NewswireNEW YORK, April 9, 2025 NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s

PR NewswireNEW YORK, April 9, 2025 NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s

Lucid Diagnostics (LUCD) announces a public offering of common stock to raise working capital and support corporate purposes. The offering proceeds will

PR NewswireNEW YORK, April 3, 2025 NEW YORK, April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s

Discover PAVmed Inc.'s Q4 2024 earnings highlights, including Lucid Diagnostics' 45% test growth, Veris Health advancements, and strategic milestones.

PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ETCompany ParticipantsMatt Riley - Senior Director of IRLishan Aklog -...

The following slide deck was published by PAVmed Inc.

PR NewswireNEW YORK, March 25, 2025 Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commerc

Revenue: $1.2 million in EsoGuard Esophageal DNA Test revenue for Q4 2024, surpassing the estimated quarterly revenue of $0.58 million.EsoGuard Test Volume: Pr

PAVmed (PAVM) set to announce Q4 earnings on March 25. EPS is estimated at -$0.40, Revenue at $0.58M.

PAVmed (PAVM) Q4 earnings preview: EPS estimated at -$0.40 (+69.9% Y/Y), revenue at $0.58M (-44.8% Y/Y).

PR NewswireNEW YORK, March 20, 2025 Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Te

PR NewswireNEW YORK, March 18, 2025 Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of i

PR NewswireNEW YORK, March 13, 2025 Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancerNEW YORK, Marc

PR NewswireNEW YORK, March 10, 2025 Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nas

PR NewswireNEW YORK, March 4, 2025 NEW YORK, March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s

PR NewswireNEW YORK, Feb. 27, 2025 Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigator